Protein kinase inhibitors represent a major advance in cancer treatment due to their ability to target the specific kinases involved in tumor growth and survival. More than 80 small-molecule protein ...

If cells are the factories, proteins are the workers. They control nearly every aspect of cell function, from structure to signaling, from transport to defense. And, like many workers, they rarely act ...

Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...

Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review ...

As society ages, the number of patients with heart failure is rapidly increasing. The progression of the disease is caused by excessive growth of fibrotic tissue in the heart, known as fibrosis. A ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

This important paper presents a rigorous and comprehensive deep mutational analysis of the kinase TYK2, revealing how single amino acid substitutions influence protein abundance, signaling activity, ...

Patients with rheumatoid arthritis (RA) tolerated a novel Janus kinase/Roh-associated protein kinase (JAK-ROCK) inhibitor without typical side effects. Phase 2 clinical trial at nine hospitals and ...

BTK inhibitors have transformed B-cell malignancy treatment, with distinct resistance mechanisms linked to specific inhibitors. Covalent inhibitors often lead to BTK C481 mutations, while non-covalent ...

Most patients with vascular anomalies treated with the mitogen-activated protein kinase (MEK) inhibitors, trametinib and selumetinib, experienced cutaneous adverse events (CAEs). “Multidisciplinary ...